Cell surface receptors play major roles in signal transduction. Many of them exist as dimers, but the precise conformational changes leading to their activation remain largely unknown. Some of these receptors have a large ECD that is involved in agonist binding. Conformational changes in ECDs resulting from agonist binding have to affect the conformation of the effector domain for the signal to be transduced inside the cell.
Cell surface receptors play major roles in signal transduction. Many of them exist as dimers, but the precise conformational changes leading to their activation remain largely unknown. Some of these receptors have a large ECD that is involved in agonist binding. Conformational changes in ECDs resulting from agonist binding have to affect the conformation of the effector domain for the signal to be transduced inside the cell.
The structures of dimeric ECDs of many membrane receptors, including some tyrosine kinase [1] [2] [3] [4] , guanylate cyclase [5] [6] [7] and G-protein coupled receptors (GPCRs) [8] [9] [10] [11] , have been solved by X-ray crystallography in the absence or presence of agonists. Accordingly, initial steps leading to receptor activation have been proposed, but they remain to be confirmed in full-length receptors.
The mGlu 1 receptor is one of the dimeric receptors for which important information has been obtained by X-ray crystallography 8, 9 . This receptor belongs to class C of GPCRs, which includes the eight mGlu receptors, the γ-aminobutyric acid type B (GABA B ) receptor, the Ca 2+ sensing receptor and some taste and pheromone receptors 12 . In addition to the heptahelical domain (HD) common to all GPCRs, class C receptors have a large ECD composed of a Venus flytrap domain (VFT) where agonists bind and a cysteine-rich domain (CRD).
The resolution of the structure of mGlu 1 VFT 8, 9 , expressed as a soluble protein, confirmed several features suggested previously 13, 14 : (i) this domain is structurally similar to some bacterial periplasmic proteins and is composed of two lobes separated by a cleft where ligand binds; (ii) the VFT, in an open conformation in the absence of ligand or with bound antagonist, can adopt a closed conformation upon agonist binding; (iii) these soluble VFTs are associated in homodimers at the level of their lobe I by hydrophobic interactions and a disulfide bridge.
The most notably observation is the existence of two possible relative orientations of the VFTs within the dimer. The first orientation is observed in the absence of agonist or in the presence of an antagonist, and is therefore called 'resting.' In this case, both VFTs are open (Roo) and the lobes in the two ligand-binding domains that connect the HD (lobe II) are far apart (Fig. 1) . The second orientation is observed in the presence of agonists, and is therefore called 'active.' In this case, either one (Aco) or both (Acc) VFTs are in a closed state and the lobes II become closer and directly contact each other (Fig. 1) . Moreover, binding of a cation like Gd 3+ , which is an mGlu 1 potentiator, at the lobe II interface has been proposed to favor the Acc conformation 8 .
We have previously shown that, in full-length receptors, agonists act by stabilizing a closed state in at least one VFT whereas antagonists prevent such closure. Indeed, the insertion of two cysteines expected to close the VFT of the GABA B1 receptor lead to a constitutively fully active receptor 15 . Moreover, mutation of residues that prevent the closure of the mGlu 8 VFT upon binding of two distinct antagonists allows these molecules to act as full agonists 16 . However, it is still unknown whether both Acc and Aco conformations of the dimer of VFTs correspond to active receptor conformations. It is also unclear whether binding of two agonists per dimer is required for activation of class C GPCRs. In the case of the heterodimeric GABA B receptor, which is composed of the GABA B1 and GABA B2 subunits, it has been shown that agonist binding occurs in the GABA B1 VFT only 17 , but what about homodimeric mGlu receptors?
In the present study we examined whether the binding of one or two agonists is required to activate homodimeric mGlu receptors. We also examined whether the Aco conformation of the dimer of VFTs corresponds to a fully active receptor. To that aim, we developed a system that allows the surface expression of dimeric combinations composed of two defined subunits, with or without specific mutations. Here we show that although binding of a single agonist is sufficient to activate mGlu 5 receptor, a second is required for full activity. Our data also show that only the Acc conformation leads to full activity and that the Aco conformation corresponds to a partially active state of the dimer.
RESULTS

Generation of 'heterodimeric' mGlu 5 receptor
To examine the specific role and possible conformation of each VFT in a dimeric mGlu receptor, it is necessary to have access to dimeric receptors composed of two defined subunits, one with and one without mutations affecting ligand recognition.
To that aim, we took advantage of the quality control system of the GABA B receptor [18] [19] [20] . We first replaced the C-terminal tail of mGlu 5 by that of the GABA B1 subunit containing the endoplasmic reticulum (ER) retention signal RSRR (Fig. 2a) . As expected, the mG5C1 chimera was not targeted to the cell surface as shown by both immunofluorescence and ELISA experiments conducted on intact cells (Fig. 2b,c) . Mutation of the ER retention signal into ASAR 19 allowed the receptor to reach the cell surface and to activate phospholipase C (PLC) (quisqualate EC 50 = 56 ± 10 nM), demonstrating that the C-terminal tail of GABA B1 does not prevent coupling to Gq (Fig. 2d) .
A second mGlu 5 chimera was generated in which the C-terminal tail was replaced by that of GABA B2 (Fig. 2a) . This C-terminal tail had a determinant that can mask the ER retention signal of GABA B1 in GABA B1 -GABA B2 heterodimers 18, 19 . When expressed alone, this mG5C2 chimera is correctly targeted to the cell surface and is still functional (Fig. 2b-d ) (quisqualate EC 50 = 69 ± 16 nM).
When HA-mG5C1 was coexpressed with myc-mG5C2, HA-mG5C1 reached the cell surface (Fig. 2b,c) , demonstrating that GABA B2 tail exerts its action even in the mGlu 5 environment. Because mGlu 5 dimers are linked by a disulfide bridge 14, 21, 22 , it is likely that the dimers formed in the ER are stable even at the cell surface. As such, in cells expressing both mG5C1 and mG5C2, one would expect that mG5C1 homodimers would be retained in the ER, whereas mG5C2 homodimers as well as mG5C1-mG5C2 heterodimers would reach the cell surface (Fig. 3a) .
In agreement with this proposal, the presence of mG5C1-mG5C2 heterodimers at the cell surface was firmly established on intact cells using HTRF (homogeneous time-resolved fluorescence resonance energy transfer (FRET)) 23 . To that aim, we used anti-HA and anti-myc labeled with donor and acceptor fluorophores, respectively 24 (see Methods). A clear FRET signal was observed with HA-mG5C1 and myc-mG5C2, similar to the signal measured with HA-GABA B1 and myc-GABA B2 (Fig. 3b) . At an equivalent expression level (Fig. 3c) , no such signal was observed when the two tagged proteins were independently labeled in different cells or when HA-mG5C2 was coexpressed with myc-V2 vasopressin receptors (Fig. 3b) . The FRET signal of mG5C1-mG5C2 is directly proportional to the amount of mG5C1 at the cell surface. Furthermore, in these same cells, no significant FRET signal could be measured between two HA-mG5C1 when using a mixture of anti-HA labeled with either fluorescent donor or acceptor molecules (Fig. 3d) , demonstrating that HA-mG5C1 homodimers (or tetramers composed of two mG5C1-mG5C2 heterodimers) were not present at the cell surface. By contrast, a clear signal was measured using the same anti-HA in cells expressing HA-mGlu 5 homodimers 24 .
mGlu 5 mutants insensitive to agonists
We next aimed to generate mGlu 5 mutants that could no longer be activated by agonists to produce dimers with a single wild-type agonist-binding site. Accordingly, mutations were introduced either in lobe II (Y222A D304A), or in lobe I (S151A T174A or Y64A T174A) based on a three-dimensional model of the mGlu 5 VFT generated as described 16 (Fig. 4a) . These three mutants were called mGlu 5 -YADA, SATA and YATA, respectively. These mutations were also introduced into both the HA-and the myc-mG5C2 chimeras. Cells expressing any of these mutants were not able to produce inositol phosphates even upon stimulation with 10 mM glutamate or quisqualate, a highly potent mGlu 1 -mGlu 5 selective agonist (Fig. 4b) . This is most likely due to the inability of these agonists to activate the receptor because all mutant receptors were found at the cell surface at a density similar to the nonmutated controls, as revealed by ELISA (data not shown).
One agonist per dimer is sufficient for activation According to the data described above, any measured response in cells expressing mG5C1 and mG5C2-YADA would be generated by the heterodimer mG5C1-mG5C2-YADA (Fig. 5a) . A biphasic dose-response curve was observed (Fig. 5b) . The first response occurred with an EC 50L of 304 ± 152 nM, higher than that measured on the control dimer (48 ± 8 nM), and plateaued at 25-30% of the maximal response of the control dimer. This is consistent with a three-fold decrease in coupling efficacy as the inositol phosphate response was previously shown to be directly proportional to the amount of mGlu 5 receptors at the cell surface 25 . A second response occurred at higher concentrations of quisqualate (EC 50H = 208 ± 32 µM) and reached a maximum of ∼80% of that measured with the control receptor. A similar biphasic response was also obtained when the intracellular Ca 2+ signal was measured instead of inositol phosphate production (Fig. 5c) . Because the EC 50L is close to that measured on the wild-type receptor, it is likely that the first component of this response results from quisqualate binding in the wild-type subunit only.
A second agonist provides maximal activity
The second phase of the response measured with the mG5C1-mG5C2-YADA heterodimer is probably due to quisqualate activation of the second mutated VFT, an effect made possible by the agonist-occupied wild-type VFT. In agreement with this proposal, the EC 50L of quisqualate did not depend on the mutations introduced in the mutated subunit (304 ± 152, 301 ± 115 and 218 ± 80 nM for the combinations containing mG5C2-YADA, YATA and SATA, respectively), but EC 50H largely varies depending on the mutant subunit used (208 ± 32, 972 ± 108 and 1,576 ± 246 µM for mG5C2-YADA, YATA and SATA, respectively) (Fig. 5d) .
Accordingly, although one ligand seemed sufficient to activate the receptor, the activation was partial, and only binding of two agonists could maximally activate such dimeric receptors.
The Aco conformation is partially active
There are two possibilities to explain the observation that one ligand per dimer partially activates the receptor assuming the bound VFT is in a closed state. The first is that the Aco conformation is sufficient to partially activate the receptor. The second is that the closed liganded VFT can in turn favor the closure of the second unliganded VFT leading to a certain proportion of the monoliganded receptors in the active Acc state.
To examine whether the Aco state is sufficient to activate the receptor, we generated a mGlu dimer in which one VFT can be stabilized in a closed state by an agonist, and the second VFT can be maintained open by an antagonist. To that aim, we generated a subunit composed of the mGlu 2 VFT, the HD of mGlu 5 and the C terminus of GABA B2 (mG2/5C2, Fig. 6a ). Such a chimeric receptor can reach the cell surface, be activated by the selective mGlu 2 agonist DCG-IV, and be antagonized by the selective mGlu 2 antagonists PCCG-IV, MCCG-I and LY341495 (ref. 26) . Moreover, this chimera is insensitive to the mGlu 5 agonist quisqualate and brings mG5C1 to the cell surface (data not shown).
Quisqualate activates the mG5C1-mG2/5C2 heterodimers (EC 50 = 251 ± 109 nM), an effect that is not altered by mGlu 2 selective antagonists ( Fig. 6 ) (quisqualate EC 50 = 251 ± 109; 219 ± 53; 275 ± 105 and 209 ± 7 nM under control conditions and in the presence of PCCG-IV, MCCG-I or LY341495, respectively). As shown below, this is not due to the inability of these antagonists to act in mG2/5C2 within such a heterodimer. Assuming the antagonist prevents the closure of the mG2/5C2 VFT, this demonstrates that the Aco state of the VFT dimer is sufficient to partially activate the receptor. 
Signal transduction within the 'heterodimer'
In a homodimeric receptor, both HDs are identical and potentially share the same capacity to activate G proteins. Accordingly, and in agreement with previous studies 27 , dimers in which one HD only was mutated in its i3 loop (F767S) to prevent G-protein coupling 28, 29 (mG5C1-i3 + mG5C2 or mG5C1 + mG5C2-i3) are still functional but the maximal stimulation is decreased by ∼50% despite a similar expression level of all combinations (Fig. 7a) .
Accordingly, one possible interpretation for the partial activity of the dimer is that an agonist-liganded VFT leads to the activation of either the HD of the same subunit (cis-activation, Fig. 7b) or that of the other subunit (trans-activation, Fig. 7b) . Then, full activity can only be obtained upon agonist binding in both VFTs.
To determine which mechanism occurs during the activation process, we examined the effect of the i3 loop mutation in either HD within the heterodimer mG5C1-mG5C2-YADA. Indeed, in the case of cis-activation, the i3 mutation introduced into mG5C1 should prevent the first component of the agonist dose-response curve only. The second component should remain intact. In contrast, in the case of transactivation, such a mutation would be expected to suppress the second phase only. The reverse would be expected if the i3 mutation were introduced into mG5C2-YADA. Whether the i3 mutation was introduced in mG5C1 or in mG5C2-YADA, a decrease in the maximal response of both the first and the second phase was observed despite a similar expression level of the different constructs (Fig. 7c) . This indicates that both HDs contribute to the two activated states of the receptor. Accordingly, a single agonist-occupied VFT can activate either HDs (or both), consistent with both cis-and trans-activation occurring in these dimeric receptors (Fig. 7d) .
The Acc conformation is required for full activity
Our data demonstrate that two agonists are required for full activation of mGlu receptors, suggesting that both VFTs must reach a closed state. To support this, we further examined the properties of the mG5C1-mG2/5C2 heterodimer. However, when these two subunits are coexpressed, part of the response mediated by glutamate that activates both mGlu 2 and mGlu 5 VFTs may result from the activation of mG2/5C2 homodimers (Fig. 8) . To avoid this possibility, the mG2/5C2 subunit was mutated in its i3 loop. The mGlu 5 selective agonist quisqualate stimulated inositol phosphate formation but its maximal effect was about half of that obtained with the nonselective agonist glutamate (Fig. 8a) . Because inositol phosphate formation has previously been shown to be proportional to the amount of receptors at the cell surface 25 , this finding indicates that selective activation of mG5C1 leads to a two-fold lower coupling efficacy. Further addition of a (a) Left, schematic representation of combinations present at the surface of cells coexpressing mG5C1 and mG2/5C2-i3. Homodimers of mG2/5C2-i3 were inactive because they did not couple to G proteins. Quisqualate activated mG5C1 VFT only, whereas the mGlu 2 specific agonist (DCG-IV) activated mG2/5C2-i3 VFT only. Right, inositol phosphate (IP) production in cells coexpressing mG5C1 and mG2/5C2-i3 upon stimulation with increasing concentrations of quisqualate (Quis) or DCG-IV in the presence of quisqualate (10 -4 M). (b) Similar experiment to that in a, but with glutamate, which activates both VFT, and LY341495, an mGlu 2 antagonist. Right, IP production in cells coexpressing mG5C1 and mG2/5C2-i3 upon stimulation with increasing concentrations of LY341495 in the presence of 3 × 10 -3 M glutamate, or with increasing concentrations of glutamate. mGlu 2 agonist (LY354740 or DCG-IV) increased the maximal quisqualate effect to reach the response obtained with glutamate (Fig. 8a) . Moreover, the effect of glutamate was inhibited by 50% by LY341495, which would be expected to prevent the closure of the mGlu 2 VFT (Fig. 8b) , further demonstrating that the closed state of both VFTs is required for full activity.
Notably, mGlu 2 selective agonists (≤1 mM) did not activate this receptor combination on their own, suggesting that the closure of the mGlu 2 VFT cannot trans-activate the HD of mG5C1. This is in contrast to the clear trans-activation we observed with the mG5C1-mG5C2-YADA dimer (Fig. 7c) . This is probably due to the chimeric nature of the dimer of VFTs in the mG5C1-mG2/5C2-i3 combination. It is possible that the Aco dimer in which the mGlu 2 VFT is closed is not as stable as that in which the mGlu 5 VFT is closed, owing to the asymmetry of the lobe-II interface in this heterodimer.
To further document that the Acc conformation is required for full activity, we examined the effect of Gd 3+ on glutamate dose-response studies carried out on the mG5C1-mG5C2-YADA heterodimer. It has been proposed that a cation such as Gd 3+ stabilizes the Acc conformation 8 (Fig. 1) . We observed an increase in quisqualate potency in generating the second phase of the response in the presence of Gd 3+ (EC 50H = 51 ± 5 µM and 208 ± 32 µM, in the presence and absence of Gd 3+ , respectively), but no change in EC 50L (442 ± 201 nM). This further suggests that the second phase of the dose-response curve results from the Acc conformation of the VFT dimer.
DISCUSSION
The present study was aimed at determining which of the agonistoccupied conformations of the dimer of mGlu VFTs, the Aco and Acc conformations 8 , corresponds to the active state of full-length receptor. Our data show that the Aco and Acc conformations correspond to a partially and fully active state of the dimer, respectively.
Controlling subunit composition of the dimeric receptor
To examine the specific role of each VFT in a homodimeric mGlu receptor, we first developed a system allowing cell surface expression of functional dimeric receptors composed of two defined subunits, each bearing or not bearing specific mutations. Indeed, we show that the quality control system of the GABA B receptor [18] [19] [20] can be transferred to the mGlu 5 receptor. Thus, in cells coexpressing mG5C1 and mG5C2 chimeras that have the C-terminal tail of GABA B1 and GABA B2 , respectively, we demonstrate the existence of mG5C1-mG5C2 heterodimers at the cell surface. We also show that mG5C1 homodimers do not reach the cell surface. Finally, although mG5C2 homodimers reach the cell surface, the function of these receptors can easily be abolished by specific mutations. Accordingly, in cells expressing these two types of subunits, only the heterodimer is functional. Such a system may well be adapted to other membrane proteins for which the functional significance of dimer formation is still unknown, such as rhodopsinlike GPCRs.
One agonist is sufficient but two are better
Using this system we show that binding of a single agonist is sufficient to activate mGlu 5 dimers. This is illustrated by the first component of the agonist dose-response curve in mG5C1-mG5C2 in which mutations have been introduced in the mG5C2 binding site. Agonist potency in generating this response is six times lower than that observed with the wild-type dimer. Whether this reflects a positive allostery between the two VFTs controlling agonist affinity remains to be studied in binding experiments. That a single agonist is sufficient to activate the dimer is also confirmed by the effect of a selective mGlu 5 agonist on the mG5C1-mG2/5C2-i3 heterodimer. However, the activation was partial and only when a second agonist bound to the associated subunit was the receptor fully active. Notably, in heterodimers containing a subunit mutated in the binding site, the application of agonists seems to activate the mutated subunit at a concentration at which no effect was seen on homodimeric mutated receptors. Accordingly, agonist binding to the wild-type VFT either largely increases agonist affinity to the open state of mutated VFT, and/or allows the agonist binding to stabilize the closed state of the mutated subunit by decreasing the energy required for isomerization.
Only the Acc conformation is fully active
Our data indicate that the partial activity measured with a monoliganded dimer corresponds to the Aco conformation of the dimer of VFTs. Indeed, agonists are known to stabilize the closed conformation of the VFT, whereas antagonists prevent such a closure 8, 9, 15, 16 . Therefore, a receptor in which an agonist occupies one VFT and an antagonist is bound to the other would be expected to have one VFT in the closed state and the other in the open state. As shown with the mG5C1-mG2/5C2 response measured in the presence of an mG5C1 agonist and an mG2/5C2 antagonist, such a liganded dimer shows the same partial activity as a receptor activated by a single agonist. Several arguments are also consistent with the fully active receptor corresponding to the Acc conformation. In the case of the mG5C1-mG2/5C2 heterodimer, where agonist occupation of both VFTs is required for full activity, this activity is only partly inhibited in the presence of an antagonist acting selectively on mG2/5C2. Moreover, the second phase of the quisqualate response observed with mG5C1-mG5C2-YADA dimer is sensitive to Gd 3+ , as would be expected according to the proposed stabilization of the Acc conformation by these cations (Fig. 1) 8 .
Signal transduction within the mGlu dimer
Partial activity of mono-liganded dimeric receptors in the Aco conformation may well result from the activation of a single HD. However, our data clearly indicate that this is not the case, because even when they are activated by a single agonist, both HDs contribute to the activation of PLC. Accordingly, the closure of one VFT can turn on either its associated HD and/or that of the other subunit. This conclusion agrees well with the proposal that the change in the relative orientation of the VFTs observed between the resting and the two active states (Fig. 1) forces the HDs to interact differently, leading to their activation.
The Aco and Acc conformations of the dimer of mGlu1 VFTs have both been proposed to correspond to an active state of the receptor 9 , on the basis of the similar relative position of the C-terminal ends of these VFTs in both conformations of the dimer. Indeed, these C-terminal ends are connected to the HD via a CRD. So, why is the full activity observed only with the Acc conformation? The relative positions between the areas of the VFTs that probably face the HDs are different in the Aco and Acc conformations. Therefore, the Aco conformation could be sufficient for the dimer of HDs to reach a fully active state, but this state would not be well stabilized. Alternatively, the Aco conformation could stabilize another conformation of the dimer of HDs corresponding to a partially active state.
Comparison with the GABA B receptor
Like mGlu receptors, the GABA B receptor is a heterodimer and each subunit is composed of a VFT and an HD 17, [30] [31] [32] . Our actual knowledge of the activation mechanism of this receptor agrees well with the proposed activation mode of mGlu receptors. Indeed, GABA only binds in the GABA B1 VFT 17 , and the closure of this domain issufficient to activate the receptor 15 . In this case, full activity is obtained with a single agonist, in contrast to mGlu receptors. However, we still don't know if the GABA B2 VFT closes upon GABA B1 VFT closure. In contrast to the mGlu receptors, in which both HDs play an equivalent role in G-protein activation, the GABA B2 HD plays a prominent role regardless of whether this HD is associated with the GABA B2 or GABA B1 VFT 32, 33 . However, as observed with mGlu receptors, in a GABA B receptor combination in which both subunits have the GABA B2 HD, both HDs play an equivalent role in G-protein coupling 27 .
Two agonists to activate mGlu receptors
In contrast to the GABA B receptor, in which a single agonist is sufficient to activate the dimer, two glutamates are required to fully activate homodimeric mGlu receptors. What could be the advantage, if any, of such a complex stoichiometry? This may be the consequence of the maintenance during evolution of homodimer formation in this family of receptors, and therefore the direct consequence of symmetry. However, many mGlu receptors play a critical role in the fast modulation of synaptic transmission 34 . According to the proposed model for receptor activation, the binding of a first agonist is sufficient to partially activate the receptor, therefore rapidly leading to the fully active receptor. This may increase the probability that the receptor is activated by low concentrations of agonist. Another possibility is that as the activation system becomes more complex, it has more possibilities of regulation. For example, controlling the Aco-Acc equilibrium would have direct consequences on receptor activity. Ca 2+ seems to be a good candidate for such a role, although its action is difficult to analyze owing to the multiple cellular consequences of its removal, and also because other cations such as Mg 2+ may have a similar effect. Of interest however, Ca 2+ has been proposed either to directly activate mGlu 1 receptors or to act as a positive modulator 35 .
The T1 taste receptors are very similar to the mGlu receptors; like the GABA B receptor, they also form heterodimers. Whereas the T1R2-T1R3 heterodimer as well as the T1R3 homodimers are responsible for detecting sweetness [36] [37] [38] , the T1R1-T1R3 combination is responsible for umami taste detection 37, 39 . It is not known where the sweet and amino acid compounds bind in these receptors, but several lines of evidence suggest that they bind in the VFTs. In such receptor heterodimers, the existence of natural ligands interacting specifically with each subunits may offer a physiological role for the mechanism proposed here, allowing synergy between the effects of these taste molecules.
METHODS
Materials. L-Glutamic acid was purchased from Sigma. L-Quisqualic acid, MCCG-I ((2S,3S,4S)-2-2methyl-2-(carbxycyclopropyl)glycine), DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine) and LY491395 ((2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid) were purchased from Tocris Cookson. PCCG-IV ((2S,1′S,2′S,3′R)-2-(2′′-carboxy-3′-phenylcyclopropyl)glycine) was a gift from R. Pellicciari (University of Perugia, Perugia, Italy). Glutamate-pyruvate transaminase (GPT) was purchased from Roche. Culture medium, FCS and other products used for cell culture were purchased from GIBCO-BRL-Life Technologies. Plasmids and site-directed mutagenesis. Plasmids encoding the wild-type mGlu 5 subunits epitope-tagged at their N-terminal ends either with HA or cMyc, under the control of a CMV promoter, were described 40 . To obtain mG5C1 and mG5C2, the C terminus of HA-or Myc-mGlu 5a (His845-Stop1172) was replaced by that of GABA B1a (Thr872-Stop961) and GABA B2 (Phe760-Stop941), respectively, amplified by PCR and subcloned between the SphI and XbaI sites. Mutant subunits, carrying single or multiple mutations, were obtained using QuikChange (Stratagene). The mG2/5C2 chimera was obtained by introducing a PstI restriction site in both pRKmG5C2 (before Cys510) and pRK-mGlu 2 (after Ser498) using QuikChange and then by substitution of mGlu 2 PstI-PstI fragment by that of mG5C2. All constructions were verified by DNA sequencing (Genaxis).
Cell culture, transfection and immunofluorescence. HEK293 cells were cultured in DMEM supplemented with 10% (v/v) FCS and transfected by electroporation as described elsewhere 41 . The immunofluorescence assay was carried out as described 40 .
Cell surface quantification by ELISA was conducted as described 15 . At 24 h after transfection, cells were washed, fixed with 4% (w/v) paraformaldehyde and labeled with an anti-HA rat monoclonal antibody conjugated to peroxydase (clone 3F10; Roche) (0.5 µg ml -1 ). Antibody was detected and quantified by chemiluminescence using Supersignal West Femto (Pierce) and a Wallac Victor 2 luminescence counter (PerkinElmer Life and Analytical Science).
Inositol phosphate determination. Measurement of inositol phosphate accumulation in transfected cells was carried out in 96-well microplates as described 25 . Briefly, after overnight labeling with [ 3 H]myo-inositol, cells were stimulated for 30 min in the presence of 10 mM LiCl, with or without indicated compounds. The reaction was stopped with 0.1 M formic acid and inositol phosphates produced were purified in 96-well plates by ion-exchange chromatography. Radioactivity was measured using a Wallac 1450 MicroBeta microplate liquid scintillation counter (PerkinElmer Life and Analytical Science). Results are expressed as the ratio between inositol phosphate and the total radioactivity present in the membranes.
Time-resolved FRET experiments.
Time-resolved FRET experiments were conducted as described 24 . This methodology is based on the nonradiative energy transfer between rare earth cryptates such as europium (Eu 3+ ) cryptates and acceptor fluorophores such as AlexaFluor 647 (Molecular Probes). Briefly, cells expressing the indicated tagged receptor subunits were labeled with monoclonal anti-HA (12CA5) and/or anti-myc (9E10; American Type Culture Collection no. CRL-1729) carrying either Eu 3+ -Cryptate PBP or AlexaFluor 647 (provided by Cis Bio International Research). After washing, total Eu 3+ cryptate fluorescence and FRET signal were measured at 620 and 665 nm, respectively, 50 µs after excitation at 337 nm with a nitrogen laser using a RubyStar spectrofluorimeter (BMG LabTechnologies). The ratio R = (F 665 / F 620 ) × 10 4 , where F is the fluorescence signal measured at the indicated wavelength, was computed. The specific signal over background called ∆F was calculated using the following formula: ∆F = (R pos -R neg ) / (R neg ). R neg corresponds to the ratio for the negative energy transfer control where excess unlabeled antimyc monoclonal antibodies were added whereas R pos corresponds to the ratio for the positive energy transfer control. Total fluorescence emitted by the bound AlexaFluor 647 conjugated antibodies was measured at 682 nm after excitation at 640 nm using an Analyst plate reader (Molecular Devices).
Intracellular calcium measurements. Measurement of intracellular Ca 2+ signal in transfected cells was carried out in 96-well microplates as described 25 using the Ca 2+ -sensitive fluorescent dye Fluo-4AM (Molecular Probes). Fluorescence signals (excitation, 485 nm; emission, 525 nm) were measured using the fluorescence microplate reader Flexstation (Molecular Devices). The effect of added compounds was examined after 20 s of recording.
Data analysis. The dose-response curves were fitted using GraphPad Prism and the following equation for monophasic dose-response curves: y = [(y max -y min ) / 1 + (x / EC 50 )n H ] + y min , where EC 50 is the concentration of the compound necessary to obtain 50% of the maximal effect, and n H is the Hill coefficient. All data represented correspond to means ± s.e.m. of one representative experiment, out of three independent experiments performed in triplicate.
Molecular modeling.
The three-dimensional model of the liganded mGlu 5 VFT was generated using the coordinates of the liganded closed form of mGlu1 VFT (PDB entry 1EWK) using MODELER 5.00 (Insight-II version 2000, Accelrys), as described 16 . Figures displaying structures were prepared using SwissPdbViewer (v3.7) 42 .
